MTUS vs REGN · P/E 279, rev $1.08B vs P/E 14, rev $14.34B
Metallus, Inc (MTUS) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Metallus, Inc (MTUS) is a steel company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported MTUS revenue for 2024-12-31 was $1.08B. Net income was $1.3M. Revenue was down 20.4% from 2023-12-31 to 2024-12-31. MTUS currently screens at market cap $814.2M and trailing P/E 279.4.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
MTUS currently screens at market cap $814.2M and trailing P/E 279.4. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the MTUS and REGN stock pages for the full models.
Not investment advice.